False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations

JCO Precis Oncol. 2024 Aug:8:e2400354. doi: 10.1200/PO.24.00354.

Abstract

False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.

MeSH terms

  • Aged
  • Ataxia Telangiectasia Mutated Proteins* / genetics
  • Checkpoint Kinase 2* / genetics
  • Circulating Tumor DNA* / blood
  • Circulating Tumor DNA* / genetics
  • False Positive Reactions
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant* / blood
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics

Substances

  • Checkpoint Kinase 2
  • CHEK2 protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Poly(ADP-ribose) Polymerase Inhibitors
  • ATM protein, human
  • Circulating Tumor DNA